ALCAM and breast carcinoma: Previous studies suggested that endogenous ALCAM modified mostly by α (2,6)-sialylated glycans and recombinant glycosylated ALCAM modified mostly by α(2,3)-sialylated glycans in breast carcinoma cells showed different behaviors when binding to Gal-8 (Fernandez et al., 2016).